98TH GENERAL ASSEMBLY
State of Illinois
2013 and 2014
HB3003
 
Introduced , by Rep. Cynthia Soto
 
SYNOPSIS AS INTRODUCED:
 

 
20 ILCS 2310/2310-349 new

     Amends the Department of Public Health Powers and Duties Law of the
Civil Administrative Code of Illinois.  Creates the Childhood Cancer Research Board.  Sets forth the membership of the Board.  Provides that the  Board must review grant applications, make recommendations and comments, and consult with  the Department of Public Health in making grants from amounts appropriated from the Childhood Cancer Research Fund to public or private not-for-profit entities for the purpose of conducting childhood cancer research.
  


LRB098 10952 HLH 41560 b

FISCAL NOTE ACT MAY APPLY
 
 
A BILL FOR
 

  
HB3003LRB098 10952 HLH 41560 b


  
1    AN ACT concerning State government.
  
 
2    Be it enacted by the People of the State of Illinois,
 
3represented in the General Assembly:
  
 
 
4    Section 5. The Department of Public Health Powers and 
5Duties Law of the
Civil Administrative Code of Illinois is 
6amended  by adding Section 2310-349 as follows:
 
7    (20 ILCS 2310/2310-349 new)
8    Sec. 2310-349. The Childhood Cancer Research Board.
9    (a) The Childhood Cancer Research Board is created as an 
10advisory board  within the Department.  The Board shall consist 
11of 11 members as follows: 2 members appointed by the President 
12of the Senate; one  member appointed by the Minority Leader of 
13the Senate; 2 members appointed by the Speaker of the House of 
14Representatives; one member appointed by the Minority Leader of 
15the House of Representatives; 2 members appointed by the 
16Governor, one of whom shall be designated as chair of the Board 
17at the time of appointment; and 2 members appointed by the 
18Director.  The Director, or his or her designee, shall serve as 
19an ex officio member of the Board.  Members appointed under this 
20Section shall be experts in pediatric cancer or members of the 
21General Assembly; however, no appointing authority may appoint 
22more than one member of the General Assembly to serve during 
23the same term.  For the purposes of this Section, an "expert in 
 
 
HB3003- 2 -LRB098 10952 HLH 41560 b

1pediatric cancer" is defined as a physician  or scientist who 
2(i) holds a position of leadership in an internationally 
3recognized program of pediatric cancer research at the time of 
4his or her appointment, or (ii) is a fully tenured professor at 
5an institution of higher education.  In addition, an expert in 
6pediatric cancer must possess at least one of the following 
7qualifications: 
8        (1)  a strong track record of publication; 
9        (2)  participation in a federally-funded pediatric 
10    cancer research program; 
11        (3)  a leadership role in a national cancer research 
12    society, including the American Society of Hematology, the 
13    American Association of Cancer Research, or the American 
14    Society of Clinical Oncology; and 
15        (4)  participation in a National Cancer Institute or 
16    American Cancer Society study section. 
17    The Board members shall serve one 2-year term. If a vacancy 
18occurs in the Board membership, the vacancy shall be filled in 
19the same manner as the initial appointment. 
20    (b) Board members shall serve without compensation but may 
21be reimbursed for their reasonable travel expenses from funds 
22appropriated for that purpose.  The Department shall provide 
23staff and administrative support services to the Board. 
24    (c) The Board must review grant applications, make 
25recommendations and comments, and consult with  the Department 
26of Public Health in making grants from amounts appropriated 
 
 
HB3003- 3 -LRB098 10952 HLH 41560 b

1from the Childhood Cancer Research Fund to public or private 
2not-for-profit entities for the purpose of conducting 
3childhood cancer research in accordance with Section 6z-93 of 
4the State Finance Act. 
5    (d)  Grants shall be awarded to research projects that fall 
6within the following categories: 
7        (1)  understanding the basic biology of specific 
8    pediatric cancers using cellular and animal models; 
9        (2)  pre-clinical studies that translate basic 
10    observations into novel diagnostics or therapeutic agents 
11    specific to pediatric cancer; or 
12        (3)  support of Phase I clinical trials of new agents 
13    developed at Illinois institutions. 
14    (e)  The Board shall make its recommendations to the 
15Department no later than March 1 of the year after the 
16application is received.